(Q36576587)

15 August 2017

1 reference

title

Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors (English)

1 reference

15 August 2017

F Xavier Pi-Sunyer

1

1 reference

15 August 2017

publication date

1 June 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

14 Suppl 3

1 reference

15 August 2017

page(s)

135S-142S

1 reference

Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.293

Meta-analysis: pharmacologic treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.293

Elevated C-reactive protein levels in overweight and obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.293

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.293

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.293

Orlistat in the long-term treatment of obesity in primary care settings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.293

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.293

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.293

Weight loss reduces C-reactive protein levels in obese postmenopausal women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.293

Drug treatment of obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.293

The role of low-fat diets in body weight control: a meta-analysis of ad libitum dietary intervention studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.293

The effect of covertly manipulating the energy density of mixed diets on ad libitum food intake in 'pseudo free-living' humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.293

Dietary management of obesity: evaluation of the time-energy displacement diet in terms of its efficacy and nutritional adequacy for long-term weight control

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.293

Effects of drinks sweetened with sucrose or aspartame on hunger, thirst and food intake in men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.293

Metabolic and weight-loss effects of a long-term dietary intervention in obese patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.293

Effects of intermittent exercise and use of home exercise equipment on adherence, weight loss, and fitness in overweight women: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.293

Long-term maintenance of weight loss: do people who lose weight through various weight loss methods use different behaviors to maintain their weight?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.293

A descriptive study of individuals successful at long-term maintenance of substantial weight loss

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.293

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.293

Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.293

Randomized trial of lifestyle modification and pharmacotherapy for obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.293

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.293

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.293

The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.293

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.293

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.293

31 March 2020

Identifiers

DOI

10.1038/OBY.2006.293

1 reference

15 August 2017

1 reference